About Rite Aid Corporation
Rite Aid Corporation is a retail drugstore chain. The Company's segments include Retail Pharmacy and Pharmacy Services. The Company operates under The Rite Aid name. It operates approximately 4,560 stores in over 30 states across the country and in the District of Columbia. The Company's Retail Pharmacy segment consists of Rite Aid stores, RediClinic and Health Dialog. It sells brand and generic prescription drugs, as well as an assortment of front-end products, including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line. Its front-end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday and convenience products. The Company's Pharmacy Services segment consists of EnvisionRx, which provides a range of pharmacy benefit services.
Industry, Sector and Symbol:
- Sector: Retail/Wholesale
- Industry: Drug Stores
- Sub-Industry: Drug Retail
- Exchange: NYSE
- Symbol: RAD
- CUSIP: 76775410
- Previous Close: $5.95
- 50 Day Moving Average: $6.91
- 200 Day Moving Average: $7.43
- 52-Week Range: $5.20 - $8.77
- Trailing P/E Ratio: 75.32
- Foreward P/E Ratio: 54.09
- P/E Growth: -1.78
- Market Cap: $6.22B
- Outstanding Shares: 1,045,027,000
- Beta: 1.89
- Net Margins: 0.28%
- Return on Equity: 24.52%
- Return on Assets: 1.30%
Companies Related to Rite Aid Corporation:
- Debt-to-Equity Ratio: 11.22%
- Current Ratio: 1.63%
- Quick Ratio: 0.67%
What is Rite Aid Corporation's stock symbol?
Rite Aid Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "RAD."
Where is Rite Aid Corporation's stock going? Where will Rite Aid Corporation's stock price be in 2017?
5 analysts have issued 12-month target prices for Rite Aid Corporation's shares. Their forecasts range from $6.75 to $9.00. On average, they expect Rite Aid Corporation's stock price to reach $8.25 in the next twelve months.
When will Rite Aid Corporation announce their earnings?
Rite Aid Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, April, 5th 2017.
What are analysts saying about Rite Aid Corporation stock?
Here are some recent quotes from research analysts about Rite Aid Corporation stock:
According to Zacks Investment Research, "Rite Aid’s stringent focus on cost management, alongside strengthening its portfolio of health and wellness services has been impressive. However, the company faced challenges related to pharmacy reimbursement rate that also pressured its top-line in the second quarter of fiscal 2017. Further, these hurdles are anticipated to linger throughout fiscal 2017, thus raising concerns over the company’s near-term performance. Moreover, risks related to increased industry consolidation and intense competition from other drug-store chains cannot be ignored. Nonetheless, Rite Aid’s constant endeavors to enhance pharmacy and clinical services bode well. Further, the company remains positioned to gain from its merger with Walgreens Boots Alliance, which is now expected to close by the end of January 2017, reflecting an extension from its previous deadline. Estimates have also been stable ahead of the company's third-quarter earnings." (11/23/2016)
J P Morgan Chase & Co analysts commented, "Yesterday, MGM hosted an investor day in Las Vegas, where management provided an overview of the company’s financial outlook/guidance, its positive outlook for Las Vegas, an update on its construction projects, and various examples of how they are driving efficiency and innovating. By 2019, the company expects to achieve $4.0b of adjusted EBITDA (15%+ CAGR) and $2.075b of adjusted free cash flow (after all capex). The company also expects to achieve an investment grade credit rating, with net leverage seen declining to the low ~4x range in 2017 and low ~3x range in 2018 (pro forma 1Q16 net leverage: 4.8x). Additionally, MGM upsized its profit growth plan by $100m, now seeing $400m in savings and low 30% wholly owned domestic EBITDA margins by 2017, and also reiterated its expectation for 6%+ 2016 RevPAR growth. Given MGM’s strong operating trends, pipeline of upcoming projects, and compelling valuation of 9.3x our 2017E EBITDA, we continue to see value in the shares and reiterate our Overweight rating and $30 price target." (6/17/2016)
Who owns Rite Aid Corporation stock?
Rite Aid Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (3.27%), FMR LLC (3.12%), State Street Corp (1.82%), CNH Partners LLC (1.69%), Highfields Capital Management LP (1.44%) and Two Sigma Investments LP (1.38%). Company insiders that own Rite Aid Corporation stock include Douglas E Donley, Joseph B Anderson Jr, Marcy Syms, Robert K Thompson and Tony Montini.
Who sold Rite Aid Corporation stock? Who is selling Rite Aid Corporation stock?
Rite Aid Corporation's stock was sold by a variety of institutional investors in the last quarter, including CNH Partners LLC, FMR LLC, Raymond James Financial Services Advisors Inc., Credit Agricole S A, Guggenheim Capital LLC, Gamco Investors INC. ET AL, Dimensional Fund Advisors LP and Angelo Gordon & CO. L.P..
Who bought Rite Aid Corporation stock? Who is buying Rite Aid Corporation stock?
Rite Aid Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Public Sector Pension Investment Board, Two Sigma Investments LP, Highfields Capital Management LP, White Square Capital LLP, Asset Management One Co. Ltd., Halcyon Management Partners LP, GLG Partners LP and Allianz Asset Management AG.
How do I buy Rite Aid Corporation stock?
Shares of Rite Aid Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Rite Aid Corporation stock cost?
One share of Rite Aid Corporation stock can currently be purchased for approximately $5.95.